Johnson & Johnson
NYSE : JNJ$255.56−0.66%Oct 16 close
Financials
A full-history view is not available for the cash flow statement yet. This is the statement exactly as one filing printed it.
Consolidated Statements of Cash Flows
USD · reported units. Click a value to inspect its source.
| Reported line item | Dec 29, 2025 to Jun 28, 2026 (current) | Dec 30, 2024 to Jun 29, 2025 |
|---|---|---|
| Statement of Cash Flows [Abstract] | ||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net earnings | ||
| Adjustments to reconcile net earnings to cash flows from operating activities: | ||
| Depreciation and amortization of property and intangibles | ||
| Stock based compensation | ||
| Asset write-downs | ||
| Charges for acquired in-process research and development assets | ||
| Net loss/(gain) on sale of assets/businesses | ||
| Deferred tax provision | ||
| Credit losses and accounts receivable allowances | ||
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: | ||
| Increase in accounts receivable | ||
| Increase in inventories | ||
| Decrease in accounts payable and accrued liabilities | ||
| Decrease/(Increase) in other current and non-current assets | ||
| Decrease in other current and non-current liabilities | ||
| Net cash flows from operating activities | ||
| Cash flows used for investing activities | ||
| Additions to property, plant and equipment | ||
| Proceeds from the disposal of assets/businesses, net (Note 10) | ||
| Acquisitions, net of cash acquired (Note 10) | ||
| Acquired in-process research and development assets / related milestones (Note 10) | ||
| Purchases of investments | ||
| Sales of investments | ||
| Credit support agreements activity, net | ||
| Other (including capitalized licenses and milestones) | ||
| Net cash used for investing activities | ||
| Cash flows (used for) from financing activities | ||
| Dividends to shareholders | ||
| Repurchase of common stock | ||
| Proceeds from short-term debt, net | ||
| Repayment of short-term debt, net | ||
| Proceeds from long-term debt, net of issuance costs | ||
| Repayment of long-term debt | ||
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | ||
| Credit support agreements activity, net | ||
| Other | ||
| Net cash (used for) from financing activities | ||
| Effect of exchange rate changes on cash and cash equivalents | ||
| Increase in cash and cash equivalents | ||
| Cash and cash equivalents, beginning of period | ||
| Cash and cash equivalents, end of period |
37 line items · 2 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.